- Home
- AUPH vs BLFS Comparison
AUPH vs BLFS Comparison
Compare AUPH & BLFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- BLFS
- Stock Information
- Founded
- AUPH 1993
- BLFS 1987
- Country
- AUPH Canada
- BLFS United States
- Employees
- AUPH N/A
- BLFS N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- BLFS Medical/Dental Instruments
- Sector
- AUPH Health Care
- BLFS Health Care
- Exchange
- AUPH Nasdaq
- BLFS Nasdaq
- Market Cap
- AUPH 1.4B
- BLFS 1.2B
- IPO Year
- AUPH 1999
- BLFS 1989
- Fundamental
- Price
- AUPH $11.47
- BLFS $27.25
- Analyst Decision
- AUPH Strong Buy
- BLFS Strong Buy
- Analyst Count
- AUPH 2
- BLFS 7
- Target Price
- AUPH $13.00
- BLFS $30.86
- AVG Volume (30 Days)
- AUPH 1.9M
- BLFS 378.1K
- Earning Date
- AUPH 11-06-2025
- BLFS 11-11-2025
- Dividend Yield
- AUPH N/A
- BLFS N/A
- EPS Growth
- AUPH N/A
- BLFS N/A
- EPS
- AUPH 0.42
- BLFS N/A
- Revenue
- AUPH $260,111,000.00
- BLFS $93,468,000.00
- Revenue This Year
- AUPH $17.33
- BLFS $26.07
- Revenue Next Year
- AUPH $14.31
- BLFS $16.86
- P/E Ratio
- AUPH $27.48
- BLFS N/A
- Revenue Growth
- AUPH 25.59
- BLFS 68.16
- 52 Week Low
- AUPH $6.55
- BLFS $19.10
- 52 Week High
- AUPH $13.54
- BLFS $29.55
- Technical
- Relative Strength Index (RSI)
- AUPH 47.42
- BLFS 57.82
- Support Level
- AUPH $11.08
- BLFS $25.92
- Resistance Level
- AUPH $11.87
- BLFS $26.93
- Average True Range (ATR)
- AUPH 0.62
- BLFS 0.86
- MACD
- AUPH -0.14
- BLFS 0.08
- Stochastic Oscillator
- AUPH 44.06
- BLFS 71.39
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About BLFS BioLife Solutions Inc.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.